[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundacion Clinica Valle del Lili\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":221},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,83,110,140,172,197],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100563766","high-vs-low-segmental-hysterotomy-impact-on-uterine-wall-defects-post-cesarean-100563766",false,"NCT06620432","High vs. Low Segmental Hysterotomy: Impact on Uterine Wall Defects Post-Cesarean","High Segmental Hysterotomy vs. Low Segmental Hysterotomy: Association With the Incidence of Uterine Wall Defects After Cesarean Section","HISEAL","Inclusion Criteria:\n\n* Pregnant women aged ≥ 18 years.\n* Confirmed pregnancy through clinical history or ultrasound between 36 and 42 weeks of gestation.\n* Indication by the attending gynecologist for a first cesarean section, either emergent or elective.\n\nExclusion Criteria:\n\n* History of myometrial intervention, such as myomectomy.\n* History of genetic or acquired conditions that alter the anatomy of the uterus.\n* History of coagulation disorders.\n* History of connective tissue disorders, such as Lupus and Scleroderma, which may affect healing.\n* Hemodynamically unstable patients due to a clinical condition prior to performing the cesarean section.\n* Failure to sign the informed consent.",true,"FEMALE","18 Years",{"count":21,"type":22},168,"ESTIMATED","INTERVENTIONAL",[25],"NA","The purpose of this clinical trial is to compare the incidence of defects in the uterine wall at the site of the scar (niche) and surgical complications when using high-segment versus low-segment hysterotomy, with both cross-suturing and non-cross-suturing techniques, in pregnant patients undergoing their first cesarean section.\n\nResearchers will compare four arms:\n\n* Low Segment Hysterotomy + Crossed hysterorrhaphy\n* High Segment Hysterotomy + Crossed hysterorrhaphy\n* Low Segment Hysterotomy + Non-Crossed hysterorrhaphy\n* High Segment Hysterotomy + Non-Crossed hysterorrhaphy\n\nParticipants will:\n\n* Cesarean delivery\n* Attend a follow up appointment between 6 to 16 weeks post surgery where will be perform a transvaginal sonography.",[28],"Placenta Accreta Spectrum",[30,31,32,33],"High segmental hysterotomy","Low segmental hysterotomy","Caesarean section","hysterotomy defects","RECRUITING","2026-05-05",{"date":37,"type":38},"2026-05-07","ACTUAL",{"date":40,"type":38},"2025-06-12",{"date":42,"type":22},"2027-08-31",{"name":44,"class":45},"Fundacion Clinica Valle del Lili","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},"100618340","alcohol-psychoactive-drugs-analgesics-and-evaluation-in-penetrating-abdominal-trauma-100618340","NCT07330349","Alcohol, Psychoactive Drugs, Analgesics and Evaluation in Penetrating Abdominal Trauma","Influence of Alcohol, Psychoactive Drugs, and Analgesic Administration on the Evaluation Process in Patients With Penetrating Abdominal Trauma","DIRECT","Inclusion Criteria:\n\n* Patients presenting to the emergency department with penetrating abdominal trauma.\n* Age 14 years or older.\n* Patients evaluated and managed according to standard trauma care protocols, including immediate operative management or clinical observation with serial physical examination, as clinically indicated.\n* Patients admitted to the participating trauma centers during the study period.\n\nExclusion Criteria:\n\n* Patients transferred from another institution after initial surgical intervention.\n* Patients declared dead on arrival.\n* Patients with incomplete or missing clinical data precluding assessment of outcomes of interest.","ALL","15 Years",{"count":58,"type":22},363,"28 Days","OBSERVATIONAL","This prospective observational study aims to evaluate whether alcohol consumption, psychoactive drug use, or prior administration of analgesics affects the clinical evaluation and surgical decision-making process in patients with penetrating abdominal trauma.\n\nThe study will be conducted in two level I trauma centers in Cali, Colombia: a public university hospital and a private university hospital, both with high volumes of trauma patients and established protocols for non-operative management using serial physical examination.\n\nIn many trauma centers, serial physical examination is used to safely identify patients who require surgical intervention. However, there is concern that intoxication or altered mental status may reduce the reliability of physical examination, potentially leading to unnecessary imaging studies, delays in surgical decision-making, or non-therapeutic laparotomies. Despite this concern, available evidence supporting these assumptions is limited.\n\nPatients older than 14 years with penetrating abdominal trauma who undergo clinical evaluation to decide on surgical intervention. Patients will be classified according to the presence or absence of alcohol consumption, psychoactive substance use, or prior analgesic administration. The primary outcome is the time from hospital admission to the decision for surgical intervention. Secondary outcomes include trauma severity, need for surgery, length of hospital and intensive care unit stay, complications, and mortality.\n\nBy comparing patients with and without substance exposure across two different trauma care settings, this study seeks to determine whether serial physical examination remains a reliable and safe method for clinical decision-making in this population. The results may help optimize evaluation strategies, reduce unnecessary surgical procedures and diagnostic tests, and improve the standardization of care for patients with penetrating abdominal trauma.",[63,64,65,66],"Abdominal Injuries","Alcohol Intoxication","Substance-related Disorders","Penetrating Abdominal Trauma",[68,69,70,71,72,73],"Trauma decision making","Time to surgery","Penetrating abdominal trauma","Alcohol use","Psychoactive substances","Analgesic administration","2025-12-29",{"date":76,"type":38},"2026-01-09",{"date":78,"type":38},"2020-11-25",{"date":80,"type":22},"2026-01-30",{"name":44,"class":45},2,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":55,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":46},"100522704","non-operative-treatment-in-first-time-patellar-dislocation-100522704","NCT06086080","Non-operative Treatment in First-time Patellar Dislocation","Non-operative Treatment in First-time Patellar Dislocation: a Randomized Controlled Trial","Inclusion Criteria:\n\n\\- Patients with first episode of acute lateral patellar dislocation during the last 7 days.\n\nExclusion Criteria:\n\n\\* Patients with acute bilateral patellar dislocation.\n\n* Patients with open patellar dislocation.\n* Patients with previous knee surgery in the same knee.","10 Years","40 Years",{"count":93,"type":22},50,[25],"Study to evaluate the conservative treatment of patients after their first episode of primary lateral patellar dislocation. Randomized controlled trial with 2 groups: standard treatment (2-weeks with brace) followed by physical therapy, compared with knee taping and physical therapy. 1-year follow-up. Measurements include physical exam, radiographs and MRI. Outcomes: recurrence, lateral patellar tilt, functional scores, apprehension, pain.\n\nHypothesis: less recurrence in the knee taping group, as well as better functional scores.",[97],"Patellar Dislocation",[99,100,101],"Patellar dislocation","Brace","Knee taping","2025-03-31",{"date":104,"type":38},"2025-04-03",{"date":106,"type":38},"2023-10-02",{"date":108,"type":22},"2027-12-01",{"name":44,"class":45},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":118,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":46},"100583397","phase-1-safety-and-efficacy-trial-of-tv5m01-for-radiation-induced-mucositis-in-head-and-neck-cancer-patients-100583397","NCT06875791","Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients.","A Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Patients Undergoing Treatment for Head and Neck Cancer","TEMOR","Inclusion Criteria:\n\nAge ≥ 18 years and \\\u003C 60 years\n\nDiagnosis of HNSCC of the oral cavity, larynx, oro- and hypopharynx, diagnostic stage III-IV according to the AJCC 8th edition, scheduled to start radiotherapy\n\nAbility to swallow solids and liquids before starting radiotherapy treatment\n\nAdequate contraception for both sexes:\n\nFor women: negative pregnancy test for women of childbearing age; must be surgically sterile, postmenopausal (defined as absence of menstrual cycle for at least 12 consecutive months), or comply with an acceptable contraceptive regimen during and 3 months after the treatment period\n\nFor men: must be surgically sterile or comply with a contraceptive regimen during and for 3 months after the treatment period\n\nPerformance status (ECOG) of 0-1, measured within 72 hours prior to treatment initiation\n\nExpected life expectancy ≥ 6 months\n\nAdequate renal function \\[creatinine ≤ 1.5 times the upper limit of normal (ULN) or Glomerular Filtration Rate ≥ 50 ml\u002Fmin\\]\n\nAdequate liver function \\[total bilirubin ≤ 1.5 x ULN; AST or ALT ≤ 3 x ULN or ≤ 5 x ULN if due to tumor liver involvement\\]\n\nProvision of signed and dated informed consent before initiating any study-related procedure\n\nMeeting the diagnostic criteria for grade 1 or higher mucositis according to WHO classification\n\nMeeting the criteria for starting radiotherapy\n\nWilling and able to participate in the trial and comply with all trial requirements\n\nExclusion Criteria:\n\nPatients not eligible for radiotherapy\n\nStomatological disease such as ulcers, edema, exudation in the oropharyngeal mucosa before radiotherapy\n\nWomen who are pregnant or breastfeeding\n\nPatients allergic or sensitive to any of the compounds in the gel or study medications\n\nPresence of lesions that completely occlude the upper digestive tract\n\nPatients with a history of disorders, specifically those with psychotic psychiatric disorders such as schizophrenia, schizoaffective disorder, and delusional disorder, and substance\u002Falcohol abuse\n\nPatients participating or who have participated in another clinical trial in the last 30 days\n\nAnother uncontrollable, severe, hemodynamically unstable concurrent medical condition requiring urgent attention or threatening the patient's life\n\nReceiving chemotherapy regimens with delayed toxicity within the last 4 weeks (six weeks for nitrosourea or mitomycin C) or continuous or weekly chemotherapy regimen with limited potential for delayed toxicity within the last two weeks\n\nAny evidence of oral infection or disease in the oral cavity other than HNSCC\n\nAny important medical disease or incidental abnormal laboratory finding that could increase the participant's risk in the study (based on the investigator's judgment)\n\nConcomitant therapy with drugs that inhibit or enhance opioid action\n\nHypersensitivity to opioids, respiratory depression, obstructive airway disease, acute liver disease, seizure disorder, increased intracranial pressure, paralytic ileus, patients with known sensitivity to morphine, pheochromocytoma, acute asthma exacerbations, history of cardiac arrhythmia, heart failure.","60 Years",{"count":120,"type":22},40,[122,123],"PHASE1","PHASE2","This study is a Phase 2, double-blind, randomized controlled trial evaluating the safety and efficacy of TV5M01 (a 5% green tea and 0.1% morphine gel) compared to triple mixture (0.19% lidocaine, 0.29% nystatin, and 5.50% hydroxides) for treating radiation-induced oral mucositis in patients with head and neck squamous cell carcinoma.\n\nThe trial will enroll 40 patients (20 per group) with stage III-IV head and neck cancer receiving radiotherapy who develop grade 1 or higher mucositis. Participants will apply the assigned mouthwash three times daily from mucositis diagnosis until resolution.\n\nPrimary outcomes include safety (incidence of infections and adverse events) and efficacy (duration of grade 3-4 mucositis, days with severe pain). Secondary outcomes include quality of life and analgesic use. Randomization will use minimization methodology to balance important prognostic factors.\n\nThe study design incorporates two interim analyses after 10 and 19 participants, with clear safety monitoring and stopping rules. If successful, this trial could provide an evidence-based treatment option for radiotherapy-induced mucositis, potentially improving treatment completion rates and quality of life for head and neck cancer patients.",[126,127],"Squamous Cell Carcinoma of the Head and Neck","Oral Mucositis",[129,130],"Oral mucositis","Squamous cell carcinoma","NOT_YET_RECRUITING","2025-03-26",{"date":134,"type":38},"2025-04-01",{"date":136,"type":22},"2025-12-28",{"date":138,"type":22},"2026-12-31",{"name":44,"class":45},{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":55,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":152,"conditions":153,"keywords":157,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":46},"100487976","phase-3-whole-blood-in-trauma-patients-with-hemorrhagic-shock-100487976","NCT05634109","Whole Blood in Trauma Patients With Hemorrhagic Shock","Whole Blood vs. Blood Components Therapy in the Hemostatic Resuscitation of Severe Trauma Patients: An Open-label, Randomized, Controlled Clinical Trial","WEBSTER","Inclusion Criteria:\n\n* Adult patients (\\> 18 years)\n* Activating institutional trauma code for trauma patients with hemorrhagic shock.\n* Candidate for massive transfusion (Patient with an Assessment Blood Consumption (ABC) Score ≥ 2 or at the discretion of the treating physician)\n* Concurrent availability of whole blood or blood component therapy\n\nExclusion Criteria:\n\n* More than 4 hours from trauma to hospital admission\n* More than 2 hours from hospital admission to randomization\n* Transfusion of more than one packed red blood cell unit prior to randomization.\n* Patients who have undergone surgery (laparotomy, thoracotomy, or sternotomy) before hospital admission.\n* In-extremis patients with devastating injuries (expected to die within 60 minutes).\n* Blood group other than to O or A and positive Rh factor\n* Severe traumatic brain injury in which neurosurgical intervention is futile (partial decapitation, massive intracranial hemorrhage, or transcranial gunshot wounds).\n* Burns over 20% of the total body surface area.\n* Suspected airway burn.\n* Cardiopulmonary resuscitation (CPR) before arrival at the ED.\n* CPR for more than 5 minutes before randomization.\n* Do not resuscitate order.\n* Incarcerated\u002Fprisoners.\n* Known pregnancy in the ED.\n* Patient or legal representative who refuse to participate in clinical research studies.",{"count":149,"type":22},220,[151],"PHASE3","This study aims to evaluate among trauma patients with hemorrhagic shock the clinical impact of hemostatic resuscitation between whole blood vs. blood components therapy in the following outcomes in a hierarchical analysis: mortality at 28 days and evolution of organ dysfunction.",[154,155,156],"Trauma","Trauma Injury","Trauma, Multiple",[158,159,160,161,162,163],"whole blood","Blood Transfusion","Blood Component Transfusion","Hemorrhage","Advanced Trauma Life Support Care","Hemostatic resuscitation","2025-02-24",{"date":166,"type":38},"2025-02-27",{"date":168,"type":38},"2023-01-14",{"date":170,"type":22},"2026-03",{"name":44,"class":45},{"id":173,"slug":174,"hasResults":11,"nctId":175,"briefTitle":176,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":4},"100580896","outcomes-and-perceptions-of-the-implementation-of-the-jada-device-in-a-stage-ii-postpartum-hemorrhage-management-protocol-in-referral-hospitals-of-the-colombian-pacific-region-100580896","NCT06843265","Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region","Outcomes and Perceptions of the Implementation of the JADA Device in a Stage II Postpartum Hemorrhage Management Protocol in Referral Hospitals of the Colombian Pacific Region: a Cohort Study","JADAValle","Inclusion Criteria:\n\n* Pregnant women who are admitted to the obstetrics service scheduled for vaginal delivery in any of the participating hospitals: Fundación Valle del Lili, Hospital Universitario del Valle and Hospital Luis Ablanque de la Plata.\n* Patient admitted during the shift of one of the gynecologists trained in the use of the JADA device in the context of the research project.\n\nCriteria for the use of JADA device:\n\n* Pregnant women over or equal to 18 years of age.\n* Gestational age of pregnancy greater than 32 weeks of gestation.\n* Pregnant with vaginal delivery.\n* Pregnant with postpartum hemorrhage due to uterine atony that does not respond to treatment with uterotonics and uterine massage.\n* Postpartum hemorrhage uterine stage\u002Fstage II.\n* Vaginal delivery attended in a health institution in the context of the Hospital Padrino strategy (Fundación Valle del Lili or Hospital Universitario del Valle or Hospital Luis Ablanque de la Plata).\n\nExclusion Criteria:\n\n* Patients who, according to the attending physician's criteria, are not candidates for vaginal delivery.\n* Abnormality of the normal uterine anatomy.\n* Placental abnormalities.\n* Maternal anemia with hemoglobin less than 7 mg\u002Fdl prior to delivery.\n* Those who do not sign informed consent.",{"count":181,"type":22},24,[25],"This study focuses on postpartum hemorrhage (PPH), a condition that stands out as the leading cause of global maternal mortality. Annually, about 14 million women experience PPH, resulting in approximately 70,000 deaths. This condition presents a higher risk in low- and middle-income countries (LMICs), particularly where access to quality care is limited. Recognizing the urgency of addressing this public health problem, the Colombian Ministry of Health and Social Protection has implemented the Maternal Mortality Reduction Acceleration Plan (PARE) to improve maternal mortality indicators and meet the Sustainable Development Goals (SDGs).\n\nThe project will evaluate the results and perception of a new device in the management of stage II PPH in referral hospitals in the department of Valle del Cauca, integrated in the Hospital Padrino strategy. This initiative seeks not only to improve the understanding and treatment of PPH, but also to strengthen institutional capacities through education, creation of telecare networks and care services adapted to local needs.",[185],"Post Partum Haemorrhage",[187,188,189],"maternal mortality","Shock Index","care bundle","2025-02-20",{"date":164,"type":38},{"date":193,"type":22},"2025-06-01",{"date":195,"type":22},"2025-12-31",{"name":44,"class":45},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":204,"enrollmentInfo":205,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":46},"100510127","placenta-accreta-spectrum-topographic-classification-100510127","NCT05922397","Placenta Accreta Spectrum Topographic Classification","Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum, a Multicentric Prospective Cohort Study","Inclusion Criteria:\n\n* Pregnant woman over 18 years old.\n* Prenatal diagnosis by ultrasound or MRI of Placenta Accreta Spectrum (PAS), regardless of the suspected degree of severity of the disease.\n* Case requiring surgical management, either as scheduled or emergent procedure.\n* Application of the topographic classification of placenta accreta spectrum during laparotomy.\n\nExclusion Criteria:\n\n* None.","55 Years",{"count":206,"type":22},326,"The present study is a prospective multicenter study consisting of a cohort of patients with prenatal or intraoperative diagnosis of PAS, evaluating the clinical outcomes of the group of patients found in each category of the topographic classification. In addition, an approach to evaluate the acceptability of this classification among the obstetrician-gynecologists of the participating medical centers will be included.",[209],"Placenta Accreta",[211,212,213],"Pregnancy outcomes","Topographic classification","Placenta accreta","2025-02-10",{"date":216,"type":38},"2025-02-13",{"date":218,"type":38},"2023-05-21",{"date":193,"type":22},{"name":44,"class":45},""]